Predictive factors of response to mTOR inhibitors in neuroendocrine tumours: Table 1
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours: Table 1
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 23, Issue 3, Pages R173-R183
Publisher
Bioscientifica
Online
2016-02-10
DOI
10.1530/erc-15-0413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
- (2015) M. S. Khan et al. CLINICAL CANCER RESEARCH
- Deubiquitinases and the new therapeutic opportunities offered to cancer
- (2015) R. Pfoh et al. ENDOCRINE-RELATED CANCER
- Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
- (2015) Mark Kidd et al. ENDOCRINE-RELATED CANCER
- Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours
- (2015) C. P. Pipinikas et al. ENDOCRINE-RELATED CANCER
- Consensus on biomarkers for neuroendocrine tumour disease
- (2015) Kjell Oberg et al. LANCET ONCOLOGY
- Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
- (2015) Oncotarget
- Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors
- (2014) Jennifer Chan et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection
- (2014) Irvin M Modlin et al. ENDOCRINE-RELATED CANCER
- KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors
- (2014) Fei Yuan et al. International Journal of Biological Sciences
- Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
- (2014) S. J. van Asselt et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine Tumor Biomarkers: Current Status and Perspectives
- (2014) Irvin M. Modlin et al. NEUROENDOCRINOLOGY
- EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix
- (2014) Arno Dimmler et al. PATHOLOGY RESEARCH AND PRACTICE
- 18F-FDG and 18F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice
- (2014) Camilla Bardram Johnbeck et al. PLoS One
- Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
- (2014) Lynnette Fernandez-Cuesta et al. Nature Communications
- PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms
- (2014) Franziska Briest et al. Theranostics
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
- (2013) K. Oberg et al. CLINICAL CANCER RESEARCH
- Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility
- (2013) Irvin M. Modlin et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
- (2013) Teresa Gagliano et al. ENDOCRINE-RELATED CANCER
- Targeted therapy with kinase inhibitors in aggressive endocrine tumors
- (2013) Vincenzo Marotta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
- (2013) Zhi Rong Qian et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
- (2013) Joshua M Francis et al. NATURE GENETICS
- Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas
- (2013) Julien Bollard et al. NEUROENDOCRINOLOGY
- The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood
- (2013) Irvin M. Modlin et al. PLoS One
- Predictive value of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma
- (2012) Masayuki Inubushi et al. ANNALS OF NUCLEAR MEDICINE
- The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy
- (2012) S. Serra et al. CANCER RESEARCH
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Neuroendocrine tumor disease: an evolving landscape
- (2012) Andrea Frilling et al. ENDOCRINE-RELATED CANCER
- Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms
- (2012) Kathrin Zitzmann et al. ENDOCRINE-RELATED CANCER
- Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors
- (2012) Mohid S. Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors
- (2012) Marianne Pavel NEUROENDOCRINOLOGY
- Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors
- (2012) Judith A. Gilbert et al. PANCREAS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors
- (2011) M. S. Khan et al. CLINICAL CANCER RESEARCH
- The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases
- (2011) Chen-Fei Zhou et al. HEPATO-GASTROENTEROLOGY
- Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus
- (2011) James C. Yao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges
- (2011) Laura Catena et al. Targeted Oncology
- Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
- (2011) Catherine Delbaldo et al. Targeted Oncology
- Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
- (2010) Irvin M. Modlin et al. ANNALS OF SURGICAL ONCOLOGY
- Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung
- (2010) Luisella Righi et al. ENDOCRINE-RELATED CANCER
- mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
- (2010) A. Kasajima et al. ENDOCRINE-RELATED CANCER
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
- (2010) Christopher W. Chiu et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice
- (2010) Mette Munk Jensen et al. PLoS One
- Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
- (2009) T. Donnem et al. ANNALS OF ONCOLOGY
- Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
- (2009) Takashi Shida et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung
- (2009) Felicia S. Falvella et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Biochemical Testing for Neuroendocrine Tumors
- (2009) Aaron I. Vinik et al. PANCREAS
- Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
- (2008) A. Moreno et al. ENDOCRINE-RELATED CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
- (2008) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- (2008) L S Steelman et al. ONCOGENE
- Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
- (2007) Simona Grozinsky-Glasberg et al. NEUROENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now